The $30 Billion Wipeout That Started With a Bad Test Design

Adding Wainua on top of that showed no treatment effect whatsoever. Zero. The stabilizer patients did about the same whether they got Wainua or placebo.

But buried in a prespecified subgroup analysis, there was a glimmer. Patients who received Wainua as monotherapy (no stabilizer) showed a 29% risk reduction compared to placebo, with a hazard ratio of 0.71. That's not nothing. In most other contexts, a 29% reduction in cardiovascular death and events would make headlines for the right reasons.

The problem? That finding was "nominally significant," which in clinical trial language means it's interesting but not statistically rigorous enough to hang a regulatory application on. Stifel analyst Paul Matteis put it bluntly, writing that approaching regulators with this data "would seem like a stretch."

A Self-Inflicted Wound?

Multiple analyst teams zeroed in on the trial design as the core issue. If you're testing whether a new drug works, and most of your patients are already on an effective therapy, you've created a very high bar for your drug to clear. It's like trying to prove a new espresso machine makes better coffee, but you're testing it on people who already had a perfect cup five minutes ago. The incremental benefit gets buried.

Bank of America noted that investors weren't expecting this outcome, especially after Alnylam's competing RNA therapy, Amvuttra, had posted positive results in a similar setting. The surprise made the sell-off that much sharper.

Jefferies analyst Michael Leuchten told clients the miss doesn't derail AstraZeneca's goal of $80 billion in revenue by 2030, but it "somewhat dents management's credibility." That's a polite way of saying: you told us this would work, and your trial design choices are now under a microscope. Jefferies pointed out that AstraZeneca is usually praised for smart trial design, making this stumble feel uncharacteristic.

The Damage Report: Two Companies, Very Different Bruises

AstraZeneca's stock dropped about 6 to 10% on the news, painful but manageable for a company with 194 pipeline projects and more than 100 ongoing Phase 3 studies. The ATTR-CM opportunity for Wainua was worth an estimated $5 billion or more in peak annual sales, which hurts but represents a meaningful chunk of AstraZeneca's total valuation. Barclays projects AstraZeneca is unlikely to run another large monotherapy trial for Wainua in heart disease, effectively ceding the ATTR-CM market to Alnylam.

Ionis took the harder hit. Its shares plummeted roughly 20 to 24%, reflecting the company's much greater dependence on eplontersen as a growth engine. The lost milestones, royalties, and profit-sharing from an ATTR-CM approval would have been transformative revenue for a company of Ionis's size. Reports have surfaced of a shareholder investigation into whether management was transparent enough about trial risks and design choices before the results dropped.

What It Means for RNA Heart Drugs

The billion-dollar question: is this a failure of the drug, the disease approach, or the entire concept of using RNA-silencing technology in cardiology?

Most experts are landing on "none of the above, exactly." The monotherapy signal suggests eplontersen does something meaningful when it's not competing with stabilizers. The antisense platform itself continues to show powerful target engagement across cardiovascular targets. Ionis and AstraZeneca's own partnership includes other RNA-based programs in kidney disease, liver disease, and lipid disorders that aren't affected by this result.

But the broader RNA-in-cardiology field is still operating in what you might call a "pre-proof" era. No antisense drug has yet demonstrated reduced cardiovascular events in a completed Phase 3 outcomes trial, full stop. Novartis's pelacarsen (targeting a heart-attack risk factor called Lp(a)) is expected to report HORIZON trial results in the first half of 2026, and that readout just became even more consequential. A win there would validate the platform. Another miss would trigger a much deeper reckoning.

The Road From Here

Both companies plan to present the full CARDIO-TTRansform dataset at the European Society of Cardiology (ESC) Congress this month. The subgroup data, safety details, and secondary endpoints could reshape the narrative, or confirm it.

For AstraZeneca, this is a speed bump on a long highway. Its cardiometabolic strategy spans diabetes, chronic kidney disease, heart failure, and obesity, all driven by assets that have nothing to do with TTR. The company's 2030 targets remain intact according to most analyst models.

For Ionis, the road is steeper. The company needs to convince investors that its cardiovascular platform is more than one trial result. Eplontersen remains approved and selling for the nerve disease indication, and the antisense technology itself is far from discredited. But the stock price tells you what the market thinks right now: that the CV growth story just lost its main character.

Sometimes the science works and the trial doesn't. Figuring out which one failed here will define both companies' next chapter.